Pfizer Inc is a research-based, global biopharmaceutical company. The Company effectively does the management of its activities from first to last in five segments. These includes the Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health and Consumer Healthcare, and Nutrition (Michael 2012). The company has diversified the general global healthcare through the context of human and animals biologic in the essence that brings the healthcare products available to all.
The key personnel running the company as per the year 2009 the running Chairman and CEO is Jeffrey Kindler. The key marketing officers of the company was a chain of directors as follows;
The address of the company is Pfizer Inc. 235 East 42nd Street NEW YORK NY 10017-5755 Phone: +1 (212) 733-2323 Fax: +1 (302) 655-5049. The company’s headquarters is located in the New York. The company’s gross revenue per share of the cash flow was 59.0 billion.
The SWOT analysis of the company is as follows;
The general description of the company overview was to increase their profit margin and at the same time delivering superior products and services to their clients on the global overview.
The proposed new B2C or B2B model
A FAB Analysis of the new offering
In the reflection of the company’s performance since 2009 there is a clear reflection that the company has been indulged in expansive research and developmental practices. This saw the company to increase its injection of production capital in the invention of new medicines for the various kinds of illnesses around the globe. This alone saw the company injecting $8 billion of its $50 billion revenues to research and development.
The FAB analysis was as follows; and the figures are in $ dollars.
The three distinct figures illustrated by the clearly showing an increase in the company’s figures despite a little fluctuation in the profit and loss figures in the years of 2011 and 2012. The distinct advantages that are arising in the process are; increased profits and sales of the company, the diverse patients are getting more proper healthcare through the developed medicine in the industry for the various illnesses. And the third aspect is how the company spearheads its activities through the various concepts employed in the field to enhance research and development in the medicine industry. Therefore the customers will definitely benefit from the products in the context that will foresee to the increase in the use of the products. This is in relation to their subsidized prices and is effectively curative to a particular illness an individual or the animal is suffering from.
The marketing channels
In the context of marketing channels for their products the company seeks to devaluate the various channels to help the products reach to the customers in time. In this context the company focuses in increasing product lines. This is in essence of product modification and consequent repositioning along the product line of contraction.
The marketing strategies would be achieved through proper branding of the products in the market. In this essence the company focuses on increasing the brand visibility of the product in the context that customers would be in the best position to effectively identify the product easily in the market place.
Another marketing channel they plan to implement is the packaging of the product in the right attractive manner to the customers all over the diverse numerous markets around the globe. This include having a protective cover and attractive. And also be well labeled in the context that it communicates effectively the information labels and usage instructions to the users.
Segmentation
The market will be segmented in the context that all the customers will be reached with the necessary products according to their financial capabilities. Market segmentation and relevant orientation would be done to the products to reach the customers through the right channel. When the market is effectively segmented the products will be in the best position to flow to the customers in the overview that will help to easily identify the product in the market.
Conclusion
In the context that will be employed in the channeling the various animal and human biological medicine and treatment of the various illnesses will be attain effectively by the company through proper branding of the products. In this essence it will increase the products identification process to the customers. Hence easily market the products in the targeted market. Also branding will effectively in the context of increasing the repeated sales. Hence the new products in the market will be easily recognized by the customers. Hence in the longer overview the company will reach a point of increasing their profits margins and also having a good service delivery charter to the individual customers helping in curbing the various illnesses related to animals and human beings.
References
Andrew Ross Sorkin and Duff Wilson (January 26, 2009). "Pfizer Agrees to pay $68 billion for Rival Drug Maker Wyeth
The economic times(march 15th 2013) The P&L A/C page of Pfizer Ltd. presents the key P&L A/c Ratios, its comparison with the sector peers and 5 years of Profit & Loss Account Statement.
"Pfizer Leadership and Structure". (6 January 2013).
